Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 17/20 | 0.57 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.48 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25515284 | 1.00 | TLR2 (0.57) | TLR2LPAR1LPAR3 | |
| SCHEMBL18057124 | 1.00 | TLR2 (0.57) | TLR2LPAR1LPAR3 | |
| SCHEMBL10819300 | 1.00 | TLR2 (0.57) | TLR2LPAR1LPAR3 | |
| SCHEMBL11304197 | 1.00 | TLR2 (0.57) | TLR2LPAR1LPAR3 | |
| SCHEMBL15149390 | 0.92 | TLR2 (0.53) | TLR2LPAR1LPAR3 | |
| SCHEMBL102391 | 0.91 | TLR2 (0.56) | TLR2LPAR1LPAR3 | |
| SCHEMBL14950501 | 0.91 | TLR2 (0.58) | TLR2LPAR1LPAR3 | |
| SCHEMBL14924385 | 0.90 | TLR2 (0.57) | TLR2LPAR1LPAR3 | |
| SCHEMBL16475661 | 0.90 | TLR2 (0.46) | TLR2 | |
| SCHEMBL15071438 | 0.90 | TLR2 (0.57) | TLR2LPAR1LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180051285-A1 | CATIONIC LIPID | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-02-22 | — | — | US | disclosed |
| US-9803199-B2 | Cationic lipid | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-10-31 | — | — | US | disclosed |
| US-9803199-B2 | Cationic lipid | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-10-31 | — | — | US | disclosed |
| US-20160257951-A1 | NOVEL LIPID | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-09-08 | — | — | US | disclosed |
| US-20160257951-A1 | NOVEL LIPID | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160257951-A1 | NOVEL LIPID | NPC1L1, CETP, LIPC | TLR2 1446/4885LPAR1 56/4885LPAR3 77/4885 |
| US-20180051285-A1 | CATIONIC LIPID | CETP, NPC1L1, LIPA | TLR2 1013/4885LPAR1 45/4885LPAR3 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.